CAN-2

CAN-2 appears to refer to a **specific cannabis extract or cannabis strain-derived extract** evaluated in a preclinical epilepsy study, rather than a well-characterized pharmaceutical drug with a clearly established international nonproprietary name, target profile, or commercial identity. Based on the provided context, it was studied alongside cannabidiol and other cannabis extracts for anticonvulsant effects in a pentylenetetrazole-induced zebrafish seizure model. The exact chemical composition, developer, manufacturer, route, formulation details, and primary molecular target of CAN-2 are not identifiable from the available evidence, so it is best treated as an incompletely specified cannabis-derived investigational extract rather than a defined drug entity.